Stefano Zanotti

Company: Dyne Therapeutics

Job title: Vice President and Head of Neuromuscular Research,

Seminars:

Discovering the FORCETM Platform: Leveraging Potential to Deliver a Transformative Antibody- Oligonucleotide Conjugate Therapy for DM1 (Myotonic Dystrophy Type 1) 9:30 am

Uncovering pre-clinical proof-of-concept with the FORCE platform in mouse models of myotonic dystrophy type 1 Outlining the pharmacology of the FORCE platform in nonhuman primates Overcoming challenges of targeted delivery to the central nervous system with the FORCE platformRead more

day: Pre-Conference Day Track 1